THE MYXALAMIDS, NEW ANTIBIOTICS FROM MYXOCOCCUS XANTHUS (MYXOBACTERALES)
From the cell mass and culture supernatant of Myxococcus xanthus strain Mx X12 an antibiotic activity against yeasts, molds and some Gram-positive bacteria could be extracted. It consisted of 4 biologically active compounds which were named myxalamid A, B, C and D.
The main component, myxalamid B, was shown to block in beef heart submitochondrial particles the respiratory chain at the site of complex I, i.e. NADH: ubiquinone oxidoreductase.
The myxalamids are new antibiotics.
In the course of a screening program for antibiotics from gliding bacteria, an activity against yeasts and molds was discovered in a strain of the myxobacterium, Myxococcus xanthus.
As it turned out, the activity consisted of a mixture of 4 chemically Batch cultures of 100 ml in 250-m1 Erlenmeyer flasks were incubated at 32°C on a rotary shaker at 160 cycles per minute with an amplitude of 50 mm. The organism also grew very well on certain technical substrates like bakers' yeast 3 % (by fresh weight of yeast cake), Probion 1 % (single cell protein from Hoechst, Frankfurt), soy flour 1 %, or Zein 1 % (maize gluten from Maizena, Hamburg), which give all inexpensive fermentation media. Myxalamid production was about five times higher when Mx x12 was when ammonia production increased, by adding acetic acid (10%). The myxalamids were produced during the growth phase and accumulated, reaching the maximal yield of 120 mg/liter at the beginning of the stationary phase. After 50 hours fermentation the cells were separated from the supernatant by centrifugation, and the antibiotics were extracted from the cell mass with acetone. The crude extract was then purified by column chromatography as described elsewhere11). The antibiotics were also present in the culture supernatant from which they could be extracted with ethyl acetate. As the amount was small relative to that contained in the cell mass (about 5 %), the supernatant was discarded. The myxalamids formed yellowish oils. They were well soluble in dichloromethane, acetone and ethanol, only slightly in diethyl ether, and insoluble in petroleum ether. They were sensitive to oxidation, and long term storage under air led to substantial loss of material. When exposed to light, the natural cis-isomers gradually changed into the more stable all-trans configuration11). Antibiotic Activity The antibiotic spectrum of myxalamid B was determined by the agar diffusion technique using paper discs. As can be seen from Table 1 , the antibiotic was active against several molds, yeasts and Grampositive bacteria, while Gram-negative bacteria were mostly resistant.
The minimal inhibitory concentration was determined for two organisms by serial dilution assay. The bacterium, Nocardia corallina, was grown in a medium containing 0.5 % peptone from casein (tryptically digested, Merck, Darmstadt), 0.1 % meat extract (Oxoid) and 0.1 % yeast extract (Difco), the yeast, Nadsonia fulvescens, in mycophil medium (1% Phytone peptone (BBL), 1 % glucose). The test cultures were started with 5 x 106 cells/mi. Relatively high concentrations of myxalamid B, 10~20 yg/ml, were needed for complete inhibition. All organisms were also tested against the trans isomer of myxalamid B. In no case was a difference in the inhibitory efficiency observed.
Toxicity
The myxalamids proved very toxic. The acute toxicity was determined in the mouse. When applied subcutaneously, the LD100 was 3 mg/kg (1 mg/kg LD0); when applied per os, the LD100 was 10 mg/ kg (3 mg/kg LD0).
Mechanism of Action
Because of a structural analogy between the myxalamids and piericidin A (Fig. 4)15) , which is an electron transport inhibitor of the eukaryotic respiratory chain6,14), we tested the effect of myxalamid B * Tested by the agar diffusion method with paper discs of 6 mm diameter to which were applied 20 /mg of pure antibiotic dissolved in methanol and 5 pl of dimethyl sulfoxide as a diffusion aid. The test agar for bacteria contained: peptone from casein, tryptically digested (Merck, Darmstadt) 0.5%, meat extract (Oxoid) 0.1 %, yeast extract (Difco) 0.1%, agar 1.5%. The molds and yeasts were assayed on mycophil agar: Phytone peptone (BBL) 1% glucose 1 %, agar 1.6%. Air-oxidized beef heart submitochondrial particles were diluted to give a density of 2.1 mg protein/ ml. Cuvettes with an optical pathway of 1 cm were filled with 1.1 ml of the suspension and placed into the reference and sample position of a double-beam spectrophotometer.
After the baseline (trace 1) was recorded, myxalamid was added to the sample cuvette to a final concentration of 6.5 Eti. After preincubation for two minutes, NADH (final concentration 2 mM) was added to the sample cuvette. Volume corrections were performed in the reference cuvette. After two minutes the resulting difference spectrum was recorded (trace 2). Finally a few grains of solid dithionite were added to the sample cuvette to achieve full reduction of the cytochromes (trace 3). Air-oxidized submitochondrial particles were diluted as described for Fig. 6 . The time course of cytochrome b reduction was measured by dual wavelength spectroscopy at the wavelength pair 563 minus 577 run. The suspension was preincubated as described in Fig. 6 . The temperature was 5~ 10 C. At the time indicated by the arrow, either NADH or succinate were added to a final concentration of 2 mM or 5 mm, respectively. The sample cuvette contained NADH plus myxalamid B (trace 1) or plus methanol (trace 2); or succinate plus myxalamid B (trace 3) or plus methanol (trace 4).
(a band at 554 nm) by NADH (Fig. 6 ). This To decide whether myxalamid B interferes with complex I, with complex II, or with both of them, we investigated the effect of the antibiotic on the reduction kinetics of cytochrome b using either NADH or succinate as the substrate. As can be seen in Fig. 7 , myxalamid B inhibited the reduction of cytochrome b only when NADH was the electron donor.
The NADH oxidation of mitochondria from commercial bakers' yeast proved insensitive to myxalamid B. The mitochondria were isolated as described before18). A 50% inhibition of NADH oxidation was achieved only at a concentration of 60 /tM, corresponding to a dose of 260 /Lmol/mg protein.
Discussion
After myxothiazol the myxovalargins10> and the myxovirescins3), the myxalamids are the fourth new antibiotic isolated by us from myxobacteria. They were produced by Wyxococcus xanthus Mx x12 with yields up to 120 mg/liter, which is relatively high for antibiotics from myxobacteria. After their discovery in Mx x12, the myxalamids were also found in Stigmatella aurantiaca Sg a1512), in M. Myxalamid B is a new inhibitor of the electron transport in the respiratory chain. Like piericidin A6), which is structurally related15), myxalamid B specifically blocked the electron flow at complex I (NADH: ubiquinone oxidoreductase EC 1. 6.5.3) of beef heart submitochondrial particles. The high toxicity of myxalamid B for mammalian systems is thus understandable; it is in the same range or even higher than that of the piericidins16, 17) In contrast to the respiration inhibitor myxothiazol2), which acts at the cytochrome bc1segment19), myxalamid B had a relatively narrow antibiotic spectrum. Only some molds, few yeasts, and a number of bacteria, mainly Gram-positive ones, were inhibited. Piericidin A and B show a comparable toxicity for fungi, but are essentially inactive against bacteria16)
Because of the structural relationship between piericidin A (Fig. 4 ) and myxalamid B (Fig. 1) , it is interesting to compare the efficiencies of the two inhibitors. The dose required for a 50% inhibition of NADH oxidation by beef heart electron transport particles is 23~60 pmol of piericidin A per mg protein9). Myxalamid B was thus 3~7 times less effective than piericidin A. Since a FMN containing flavoprotein is a characteristic constituent of complex I8), it may be more meaningful to use this component as the reference. The FMN content of beef heart mitochondria and submitochondrial particles is 1001 50 pmol per mg protein7). Accordingly the dose required for a 50%o inhibition of NADH oxidation was l to 1.7 mol myxalamid B per mol FMN.
Our data are not sufficient to determine the stoichiometry of the inhibitor-enzyme interaction. For piericidin A it is known that it binds very tightly, readily displacing e.g. rotenone which binds at the same site in complex I9), and that there is a considerable amount of unspecific binding on beef heart5,9) as well as on Candida utilis1) submitochondrial particles. Working with [14C]piericidin A and reducing the unspecific binding by treatment with bovine serum albumin, it could be shown that 2 mol of piericidin A bind at the specific site per mol of NADH dehydrogenase5).
The resistance of the majority of yeasts and of isolated mitochondria of Saccharomyces cerevisiae to myxalamid B has its parallel in piericidin A, too. Saccharomyces yeasts and mitochondria isolated from them are insensitive to this inhibitor13). Candida (Torulopsis) utilis produces under different growth conditions two types of NADH dehydrogenases of which only one responds to piericidin A4).
The myxalamids were produced as several homologues, which were all biologically active. In addition, all-trans isomers could arise during the isolation procedure; they, too, were active. It remains to be seen whether there are differences in the efficiency of the individual compounds in different test systems as is reported for piericidin A and B16).
